Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01540682 · ClinicalTrials.gov registry record · Phase 1
MLN8237 in Head and Neck Cancer
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01540682 is a Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 9 participants.
The verdict
NCT01540682, a Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study will evaluate the initial safety and effectiveness of an investigational drug, MLN8237, added to routine radiation therapy and cetuximab in patients with head and neck cancer. This study will also determine the highest dose of MLN8237 that can be given together with cetuximab and radiation therapy without causing severe side effects.
Interventions
- RADIATION Radiotherapy
- DRUG Cetuximab
- DRUG MLN8237
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01540682
The ClinicalTrials.gov registry entry for NCT01540682 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radiotherapy is the first listed.
NCT01540682 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01540682 about?
NCT01540682 is a clinical study titled "MLN8237 in Head and Neck Cancer". This study will evaluate the initial safety and effectiveness of an investigational drug, MLN8237, added to routine radiation therapy and cetuximab in patients with head and neck cancer. This study will also determine the highest dose of MLN8237 that can be given together with cetuximab and radiatio...
What is the current status of trial NCT01540682?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2012-02.
What interventions are being tested in trial NCT01540682?
The interventions under investigation include: Radiotherapy (RADIATION), Cetuximab (DRUG), MLN8237 (DRUG).
Who is sponsoring clinical trial NCT01540682?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.